共 50 条
- [21] Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol:: first results of the music clinical trialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S432 - S432Colombel, Jean-FredericHebuterne, Xavier
- [22] Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease PatientsINFLAMMATORY BOWEL DISEASES, 2020, 26 (11) : 1669 - 1681Murate, KentaroMaeda, KeikoNakamura, MasanaoSugiyama, DaisukeWada, HirotakaYamamura, TakeshiSawada, TsunakiMizutani, YasuyukiIshikawa, TakuyaFurukawa, KazuhiroOhno, EizaburoHonda, TakashiKawashima, HirokiMiyahara, RyojiIshigami, MasatoshiNishikawa, HiroyoshiFujishiro, Mitsuhiro
- [23] CLINICAL, BIOMARKER AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB: MULTI-CENTRE REAL WORLD STUDYGASTROENTEROLOGY, 2021, 160 (06) : S705 - S706Kamperidis, NikolaosFenech, ValerieThoua, NoraCole, AlexanderSegal, JonathanPeake, SimonArebi, Naila
- [24] Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trialJOURNAL OF CROHNS & COLITIS, 2023, 17 : 564 - 564Schreiber, S. W.Lee, S.Van der Woude, C. J.Marin-Jimenez, I.Wolf, D.Schnoy, E.Salzberg, B.Busse, C.Nazar, M.Langholff, W.Borghorst, S.Gasink, C.Baker, T.Godwin, B.Feagan, B.
- [25] CLINICAL CHARACTERISTICS, CLINICAL RESPONSE, AND CLINICAL REMISSION STATUS IN ADULTS TREATED WITH USTEKINUMAB IN THE PHASE 3 UNITI STUDIES AT WEEK 6 AND WEEK 44 BY AGE AT CROHN'S DISEASE ONSETGASTROENTEROLOGY, 2021, 160 (06) : S44 - S44Cohen, Stanley A.Griffiths, Anne M.Hyams, Jeffrey S.Rosh, Joel R.Turner, DanStrauss, RichardMiao, YeVolger, Sheri
- [26] EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB RE-INDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIALGASTROENTEROLOGY, 2023, 164 (06) : S220 - S220Lee, Scott D.Schreiber, StefanJanneke, ChristienVan der WoudeMarin-Jimenez, IgnacioWolf, Douglas C.Schnoy, ElisabethSalzberg, BruceBusse, ChristopherNazar, MaciejLangholff, WayneBorghorst, StephanGasink, ChristopherBaker, ThomasGodwin, BridgetFeagan, Brian G.
- [27] Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot StudyINFLAMMATORY BOWEL DISEASES, 2024,Bertani, LorenzoAntonioli, LucaFornili, MarcoD'Antongiovanni, VanessaCeccarelli, LindaCarmisciano, LucaBenvenuti, LauraMumolo, Maria GloriaBottari, AndreaPardi, VeronicaBaiano Svizzero, GiovanniBaglietto, LauraDe Bortoli, NicolaBellini, MassimoFornai, MatteoCosta, Francesco
- [28] Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 3b SEQUENCE TrialJOURNAL OF CROHNS & COLITIS, 2024, 18 : I90 - I91Peyrin-Biroulet, L.Bossuyt, P.Regueiro, M.Schreiber, S.Gecse, K.Irving, P.D'Haens, G.Cao, Q.Neimark, E.Huang, X.Anschutz, T.Kligys, K.O'Brien, D.Panaccione, R.
- [29] A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's diseaseALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (12) : 1342 - 1352Srinivasan, Ashishvan Langenberg, Daniel R.Little, Robert D.Sparrow, Miles P.De Cruz, PeterWard, Mark G.
- [30] Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn's Disease: Results From the Phase 3B SEQUENCE TrialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S1 - S1Peyrin-Biroulet, LaurentChapman, CaseyColombel, Jean-FredericCaprioli, FlavioD'Haens, GeertFerrante, MarcSchreiber, StefanAtreya, RajaDanese, SilvioLindsay, James O.Bossuyt, PeterSiegmund, BrittaIrving, PeterPanaccione, RemoNeimark, EzequielWallace, KoriAnschutz, ToniKligys, KristinaDuan, W. RachelPivorunas, ValerieHuang, XiuBerg, SofieShu, LeiDubinsky, Marla C.